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Abstract
Background Despite increasing awareness of the disease, rates of undiagnosed psoriatic arthritis (PsA) are high in
patients with psoriasis (PsO). The validated Psoriasis Epidemiology Screening Tool (PEST) is a ﬁve-item questionnaire
developed to help identify PsA at an early stage.
Objectives To assess the risk of possible undiagnosed PsA among patients with PsO and characterize patients based
on PEST scores.
Methods This study included all patients enrolled in the Corrona PsO Registry with data on all ﬁve PEST questions.
Demographics, clinical characteristics and patient-reported outcomes were compared in Corrona PsO Registry patients
with PEST scores ≥3 and <3 using t-tests for continuous variables and chi-squared tests for categorical variables; scores
≥3 may indicate PsA.
Results Of 1516 patients with PsO, 904 did not have dermatologist-reported PsA; 112 of these 904 patients (12.4%)
scored ≥3 and were signiﬁcantly older, female, less likely to be working, and had higher BMI than patients with scores
<3. They also had signiﬁcantly longer PsO duration, were more likely to have nail PsO and had worse health status, pain,
fatigue, Dermatology Life Quality Index and activity impairment.
Conclusions Improved PsA screening is needed in patients with PsO because the validated PEST identiﬁed over one-
tenth of registry patients who were not noted to have PsA as having scores ≥3, who could have had undiagnosed PsA.
Appropriate, earlier care is important because these patients were more likely to have nail PsO, worse health-related
quality of life and worse activity impairment.
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Introduction
Psoriasis (PsO), a chronic inflammatory disease that affects the
skin, has an estimated global prevalence of 2–4%.1,2 Psoriatic
arthritis (PsA) is one of the conditions most frequently associ-
ated with PsO; up to 30% of patients with PsO – approximately
0.3–1.0% of the global population – may have a concurrent
diagnosis of PsA.3–7 The presence or absence of PsA plays a
major role in determining which therapy should be used in
patients with PsO.8 In most patients with PsO who develop PsA,
arthritis usually occurs within 10 years following the first mani-
festation of their skin disease.9 Scalp and flexural skin involve-
ment, nail lesions, certain HLA alleles and increased levels of
acute-phase proteins and matrix metalloproteinase 3 in the sera
have been implicated as risk factors for the development of PsA
in patients with PsO.10–12 Enthesitis and dactylitis are character-
istic features of PsA and are indicative of erosive forms of the
disease and worse prognostic outcomes.13,14
However, undiagnosed PsA is common in patients with PsO.
A meta-analysis revealed that between 10.1% and 15.5% of
patients with PsO may have undiagnosed PsA,15 while other
observational studies have shown that even larger proportions of
patients with PsO may have undiagnosed PsA.4,16 For example,
of 949 patients with PsO evaluated at 34 dermatology centres
across seven countries in North America and Europe, 285 (30%)
had PsA, 117 (41%) of whom were not previously diagnosed.4
Undiagnosed PsA, or even a delay in diagnosis of PsA by
6 months, may lead to physical disability and peripheral joint
erosion.17 Patients with PsA must see a rheumatologist for a
definitive diagnosis; therefore, patients in consultation with a
general practitioner or a dermatologist for their PsO and joint
pain may not receive a timely diagnosis of PsA.18 The Classifica-
tion Criteria for Psoriatic Arthritis was developed for use by
rheumatologists to classify inflammatory musculoskeletal dis-
ease, using rheumatologist assessment, diagnostic measures for
inflammatory articular disease and patient-reported symp-
toms.19 However, because most patients with PsO are under the
care of a dermatologist or general practitioner, it is necessary to
have a simple and sensitive tool that can be used by these provi-
ders to identify patients who may have early-stage PsA and
prompt a timely referral to a rheumatologist for PsA evaluation.
The currently available screening tools for PsA have been vali-
dated in various clinical settings; these tools include the Early
Arthritis for Psoriatic Patients (EARP),20 German PsO Arthritis
Diagnostic questionnaire,21 PsO Assessment Questionnaire
(PAQ),22 Psoriatic Arthritis Screening and Evaluation (PASE),23
PsO and Arthritis Screening Questionnaire (PASQ),24 Psoriasis
Epidemiology Screening Tool (PEST),18 Toronto Psoriatic
Arthritis Screening (ToPAS)25 and ToPAS 2.26 For this analysis,
the validated PEST questionnaire was selected because it is an
effective tool that can be used in clinical practice, is easy to use
(just five questions) and is available in the Corrona PsO
Registry. This questionnaire can be effectively used in non-rheu-
matology practices to detect possibly undiagnosed PsA and iden-
tify patients who may benefit from consultation with a
rheumatologist.18
In this analysis of the US-based Corrona PsO Registry, we
aimed to determine the proportion of patients with possibly
undiagnosed PsA based on PEST scores (≥3) and compared
demographic and clinical characteristics of patients with a PEST
score ≥3 with those of patients with a PEST score <3.
© 2019 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd
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Methods
Data source
The Corrona PsO Registry is a large, independent, prospective,
observational cohort of patients with PsO, launched in April
2015. Patients in this analysis were recruited from 114 private
and academic practice sites across 34 states in the United States,
with 263 participating dermatologists. As of 10 May 2018, the
Corrona PsO Registry had enrolled 4864 patients, with data on
11 562 patient visits and 3890.8 patient-years of follow-up
observation time. The mean time of patient follow-up was
1.36 years (median, 1.28 years).
All participating investigators were required to obtain full
institutional review board (IRB) approval for conducting
research involving human subjects. Sponsor approval and con-
tinuing review were obtained through a central IRB (IntegRe-
view, Corrona-PSO-500). For academic investigative sites that
did not receive a waiver to use the central IRB, full board
approval was obtained from the respective governing IRBs and
documentation of approval was submitted to the Sponsor prior
to initiating any study procedures. All registry subjects were
required to provide written informed consent prior to
participating.
Study population
Study inclusion criteria were the same as those used for enrol-
ment in the Corrona PsO Registry: ≥18 years old, diagnosed
with PsO by a dermatologist, and initiated or switched to a sys-
temic (biologic or non-biologic) PsO treatment on the enrol-
ment date or within 12 months preceding the enrolment date.
This descriptive study included all patients with PsO and non-
missing data on all five questions of the PEST questionnaire
(Table 1) at time of enrolment in the Corrona PsO Registry,
between April 2015 and June 2016. The PEST consists of five
simple yes/no questions. Each ‘yes’ answer has a value of 1 point,
and a score of ≥3 indicates risk of having PsA and that a
rheumatology referral may be needed.
Study outcomes
Data on patient demographics, treatment history, clinical
characteristics, patient-reported outcome measures and work
productivity were collected using questionnaires from patients
and their treating dermatologists at the enrolment visit. Demo-
graphics included age, sex, race/ethnicity, bodyweight, body
mass index (BMI), physician-reported history of comorbidities,
work status, family history of PsO and smoking status. Treat-
ment history included prior and current use of biologic and
non-biologic systemic therapies. Clinical characteristics evalu-
ated included PsO morphology, affected body surface area (BSA;
0–100%), Investigator Global Assessment (IGA; 0–4) and PsO
Area and Severity Index (PASI; 0–72), which measures disease
severity. Patient-reported outcome measures included patient-
reported pain and fatigue visual analog scale (VAS; 0–100), the
Dermatology Life Quality Index (DLQI; 0–30) and EuroQol
VAS (EQ VAS; 0–100). Work productivity was measured by the
Work Productivity and Activity Impairment (WPAI) question-
naire.
Data analysis
Among patients without a diagnosis of PsA at enrolment, a
descriptive summary of patient demographics, treatment history,
clinical characteristics and patient-reported outcome measures
(including quality of life measures and work productivity) was
provided. Continuous variables were summarized by the num-
ber of observations, the mean and the SD, or the median and
interquartile range; categorical variables were summarized using
frequency counts and percentages. Statistical comparisons
between PEST groups (PEST score <3 and PEST score ≥3) were
made using two-sample t-tests for continuous variables and chi-
squared or Fisher’s exact tests for categorical variables.
Results
As of June 2016, 1516 of 1529 patients (99.1%) in the Corrona
PsO Registry had non-missing data on all five PEST questions. A
total of 612 patients (40.4%) had dermatologist-reported PsA at
enrolment. Of the remaining 904 patients (59.6%) without der-
matologist-reported PsA, 112 (12.4%) had a PEST score ≥3
(Fig. 1). Of the 112 patients without dermatologist-reported
PsA who had a PEST score ≥3, patients most commonly
Table 1 Psoriasis Epidemiology Screening Tool (PEST)
Question Yes No
Have you ever had a swollen joint (joints)? □ □
Has a doctor ever told you that you have arthritis? □ □
Do your ﬁngernails or toenails have holes or pits? □ □
Have you had pain in your heel? □ □
Have you had a ﬁnger or toe that was completely
swollen or painful for no reason?
□ □
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Figure 1 Distribution of Psoriasis Epidemiology Screening Tool
(PEST) scores among patients with and without a diagnosis of
psoriatic arthritis (PsA) in the Corrona Psoriasis Registry.
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answered ‘yes’ to ‘Have you ever had a swollen joint (or joints)?’
(89%) and ‘Has a doctor ever told you that you have arthritis?’
(86%), followed by ‘Do your finger nails have holes or pits?’
(63%), ‘Have you ever had pain in your heel?’ (62%) and ‘Have
you had a finger or toe that was completely swollen and painful
for no apparent reason?’ (52%).
Demographics and treatment history
As shown in Table 2, patients with a PEST score ≥3 were signifi-
cantly older than patients with a PEST score <3 [mean (SD),
52.9 (14.4) vs. 49.2 (15.2) years, respectively; P = 0.016]. They
were also more likely to be female (55.4% vs. 42.8%; P = 0.012)
and have a higher BMI [mean (SD), 32.2 (8.0) vs. 29.5 (6.9) kg/m2;
P = 0.001], and were less likely to have a full- or part-time job
(53.2% vs. 70.9%; P < 0.001). Patients with a PEST score ≥3
were also more likely have certain comorbidities (cardiovascular
disease, serious infection, depression/anxiety, hypertension and
hyperlipidaemia) and a family history of PsO than patients with
a PEST score <3 (all P < 0.05). No differences in use of treat-
ments for PsO and smoking status were observed between
groups (Table 2).
Clinical characteristics
Patients with a PEST score ≥3 had a longer duration of PsO
[mean (SD), 17.3 (14.8) vs. 14.6 (13.2) years; P < 0.001] than
patients with a PEST score <3 (Table 2). Additionally, patients
with a PEST score ≥3 were more likely to exhibit nail PsO
(21.4% vs. 10.9%; P = 0.001; Fig. 2). However, the groups did
not differ significantly in terms of other PsO morphology sub-
groups or PsO disease severity, as measured by categorical
IGA score, per cent of affected BSA, and mean PASI score
(Fig. 3).
Patient-reported outcome measures
Among the 904 patients without dermatologist-reported PsA,
those with a PEST score ≥3 had significantly worse mean (SD)
pain [28.3 (30.6) vs. 21.3 (28.7)] and fatigue [41.7 (27.8) vs. 25.0
(26.8)] than patients with a PEST score < 3 (P = 0.015 and
<0.001, respectively; Table 3). Patients with a PEST score ≥3 also
demonstrated significantly worse mean (SD) health status [EQ
VAS, 67.0 (22.9) vs. 76.4 (21.2); P = 0.002] and DLQI score [8.1
(6.5) vs. 6.2 (5.9); P = 0.002]. Higher proportions of patients
with a PEST score ≥3 had DLQI scores of 11–20 or 21–30 (‘very
large’ and ‘extremely large’ effects on quality of life, respectively)
than patients with a PEST score <3. In the WPAI domains,
patients with a PEST score ≥3 had significantly worse mean (SD)
activity impairment than those with a PEST score <3 [24.0%
(28.6%) vs. 15.0% (23.6%); P < 0.001]; the other WPAI
domains (work time missed, impairment while working and
overall work impairment) were also worse in patients with a
PEST score ≥3, but the differences were not statistically
significant.
Table 2 Demographic, clinical and treatment characteristics of
patients with PsO and no diagnosis of PsA, stratiﬁed by PEST
score
Characteristic PEST ≥3
n = 112
PEST <3
n = 792
P value
Age, mean (SD), years 52.9 (14.4) 49.2 (15.2) 0.016
Female, n (%) 62 (55.4) 339 (42.8) 0.012
White, n (%) 96 (85.7) 593 (74.9) 0.012
Hispanic, n (%) 7 (6.5) 75 (9.6) 0.289
Bodyweight, mean (SD), kg 94.1 (25.3) 86.4 (22.6) 0.052
BMI, mean (SD), kg/m2 32.2 (8.0) 29.5 (6.9) 0.001
BMI (in kg/m2) classiﬁcations, n (%) n = 111 n = 787
Normal/underweight (<25.0) 22 (19.8) 218 (27.7) <0.001
Overweight (25.0 to <30.0) 26 (23.4) 268 (34.1)
Obese (≥30.0) 63 (56.8) 301 (38.2)
Work status, n (%) n = 111 n = 787
Full/part time 59 (53.2) 561 (70.9) <0.001
Retired 29 (26.1) 121 (15.3)
Disabled 18 (16.2) 30 (3.8)
Other 5 (4.5) 79 (10.0)
History of comorbidities, n (%) n = 112 n = 792
Cardiovascular disease† 9 (8.0) 21 (2.7) 0.003
Cancer‡ 10 (8.9) 64 (8.1) 0.759
Serious infection§ 9 (8.0) 26 (3.3) 0.015
Diabetes 16 (14.3) 85 (10.7) 0.266
Depression/anxiety¶ 28 (25.0) 113 (14.3) 0.003
Hypertension 50 (44.6) 260 (32.9) 0.014
Hyperlipidaemia 39 (34.8) 190 (24.0) 0.014
Psoriasis duration, mean (SD) years 17.3 (14.8) 14.6 (13.2) <0.001
Prior medication use, median (IQR)
Biologics†† 1 (0–2) 0 (0–1) 0.186
Non-biologic systemic therapy‡‡ 0 (0–1) 0 (0–1) 0.034
Current medication use, n (%) n = 112 n = 792
Biologic monotherapy 66 (58.9) 490 (61.9) 0.569
Biologic combination therapy 9 (8.0) 48 (6.1) 0.421
Non-biologic systemic use 37 (33.0) 254 (32.1) 0.838
Current smoking status, n (%) n = 112 n = 786
Non-smoker§§ 87 (77.7) 660 (84.0) 0.096
Current 25 (22.3) 126 (16.0)
Family history of psoriasis, n (%) 14 (12.6) 36 (4.6) <0.001
†Combined histories of myocardial infarction, acute coronary syndrome, con-
gestive heart failure and peripheral artery disease. ‡Includes non-melanoma
of the skin. §Infections that led to hospitalization or intravenous antibiotics,
including joint/bursa, cellulitis, sinusitis, Candida infections, diverticulitis, sep-
sis, pneumonia, bronchitis, gastroenteritis, urinary tract infection, tuberculo-
sis or others as speciﬁed by a physician. ¶Physician-reported depression
from the adverse event portion of enrolment form. ††Prior biologic use
included adalimumab, alefacept, certolizumab, efalizumab, etanercept,
golimumab, inﬂiximab, ixekizumab, secukinumab, ustekinumab and other
investigative biologics. ‡‡Prior non-biologic use included acitretin, apremi-
last, cyclosporine, hydroxyurea, methotrexate, mycophenolate mofetil,
sulfasalazine, 6-thioguanine, tofacitinib and other non-biologic therapies.
§§Non-smokers include never and former smokers.
BMI, body mass index; IQR, interquartile range; PEST, Psoriatic Arthritis
Screening Tool; PsA, psoriatic arthritis; PsO, psoriasis.
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Discussion
Among the 904 patients without dermatologist-reported PsA in
the US-based Corrona PsO Registry as of June 2016, 112
(12.4%) had a PEST score ≥3 at enrolment, indicating a need for
further evaluation for a possible diagnosis of PsA. Patients with
PEST score ≥3 were more likely to have nail disease, a longer
duration of PsO, a higher BMI, and worse pain, fatigue and
health-related quality of life. Given current opinion that nail dis-
ease and obesity are among the strongest predictors for develop-
ment of PsA,27 these results also suggest that further evaluation
for a possible diagnosis of PsA is needed for patients with a PEST
score ≥3.
Results of screening questionnaires administered by dermatol-
ogists, such as PEST, may allow for timely rheumatologist refer-
ral and lead to earlier diagnosis of PsA in patients with PsO.
PsO Morphology
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Figure 2 Psoriasis (PsO) morphology in patients stratiﬁed by
Psoriasis Epidemiology Screening Tool (PEST) score; *P < 0.05.
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Figure 3 Disease severity among patients with Psoriasis Epidemiology Screening Tool (PEST) scores ≥3 and <3 as measured by (a) cat-
egorical Investigator’s Global Assessment (IGA) score, (b) per cent of affected body surface area (BSA) and (c) mean Psoriatic Arthritis
Severity Index (PASI) score.
Table 3 Patient-reported outcome measures for patients with PsO and no diagnosis of PsA, stratiﬁed by PEST score
Characteristic PEST ≥3
n = 112
PEST <3
n = 792
P value
Patient pain (VAS 0–100), mean (SD) 28.3 (30.6) 21.3 (28.7) 0.015
Patient-reported fatigue (VAS 0–100), mean (SD) 41.7 (27.8) 25.0 (26.8) <0.001
EQ VAS (0–100), mean (SD) 67.0 (22.9) 76.4 (21.2) <0.001
DLQI (0–30), mean (SD) 8.1 (6.5) 6.2 (5.9) 0.002
DLQI (‘effect on life’), n (%) n = 112 n = 792
None (0–1) 21 (18.8) 196 (24.7) 0.035
Small (2–5) 27 (24.1) 258 (32.6)
Moderate (6–10) 27 (24.1) 160 (20.2)
Very large (11–20) 33 (29.5) 145 (18.3)
Extremely large (21–30) 4 (3.6) 33 (4.2)
WPAI summary scores
Currently employed, n (%) 60 (53.6) 561 (71.0)
WPAI domains, mean (SD) [n]
% Work time missed 2.9 (7.9) [n = 57] 2.6 (10.7) [n = 505] 0.795
% Impairment while working 13.3 (21.9) [n = 57] 10.2 (18.7) [n = 502] 0.238
% Overall work impairment 14.8 (23.5) [n = 57] 11.5 (20.2) [n = 502] 0.251
% Activity impairment 24.0 (28.6) [n = 111] 15.0 (23.6) [n = 787] <0.001
DLQI, Dermatology Life Quality Index; EQ VAS, EuroQol visual analogue scale; PEST, Psoriasis Epidemiology Screening Tool; PsA, psoriatic arthritis; PsO,
psoriasis; VAS, visual analog scale; WPAI, Work Productivity and Activity Impairment.
© 2019 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd
on behalf of European Academy of Dermatology and Venereology.
JEADV 2019, 33, 886–892
890 Mease et al.
Because joint erosions have been documented in 27% of patients
within 10 months of PsA onset and in 47% of patients within
2 years, early screening and diagnosis of PsA may result in ear-
lier therapeutic intervention28; observational studies have shown
improved patient outcomes in patients with PsA who are treated
soon after a diagnosis of PsA.17,29,30 In addition, improved out-
comes after early detection and treatment may be long-term, as
shown in a study of the Swedish Early PsA Register, in which a
shorter duration of PsA symptoms and lower health assessment
questionnaire scores independently predicted achievement of
minimal disease activity at the 5-year follow-up.31 Furthermore,
the long-term burden of PsA eventually increases the mean cost
of health care, particularly among those with critical loss of
physical function.32 Therefore, the loss of productivity and the
availability of effective treatment also warrant earlier screening
and detection of PsA.33
Some of the screening tests developed for PsA present unique
features that may be advantageous in clinical settings. For
instance, the PASE can also be used to monitor a patient’s
response to therapy,23 while the PEST, PASQ and ToPAS ques-
tionnaires include visual aids so that patients can quickly and
easily identify areas of pain, stiffness or swelling.18,24,25 The PEST
showed high specificity and sensitivity during its development,18
with similar results in one real-world study of patients with PsO
evaluated by a dermatologist.34 Lower specificity of PEST was
observed in another real-world study, but this may have been
related to study design and patient population, and the results
were still comparable to those with other screening tools.35 The
PEST demonstrated superior performance compared with PAQ,
with a sensitivity of 0.92 and a specificity of 0.78.18 Two ‘head-
to-head’ evaluations of three screening tools (comparing PASQ,
PEST and ToPAS and PEST, EARP and PASE, respectively) in
detecting PsA concluded that the PEST had the most favourable
balance between sensitivity and specificity to screen for PsA.25,36
Additional head-to-head comparisons with other available tools
should be performed to determine the optimal tool to identify
patient populations at risk for developing PsA, thus leading to
earlier accurate diagnosis and treatment of PsA in clinical prac-
tice.36 The use of screening tools can be beneficial in the detec-
tion of PsA, and comprehensive efforts to validate them in
multiple clinical settings must continue, along with collection of
critical feedback from patients and clinicians.
As with any observational study, there are possibilities of
other unmeasured confounding variables. Care received by
patients enrolled in the Corrona registry may not be representa-
tive of the frequency or type received by the general population
of patients with PsO. All diagnoses of PsA were reported by der-
matologists, and confirmation by a rheumatologist is not
reported. Some patients may have had musculoskeletal symp-
toms that resulted in evaluation for PsA by their dermatologists
and a subsequent diagnosis of another non-PsA musculoskeletal
disorder (e.g. osteoarthritis or fibromyalgia). Additionally, all
patients initiated or switched to a systemic biologic or non-bio-
logic for treatment of PsO within 12 months of enrolment,
which may have selected for patients with unstable or more
active disease. Some of these agents are indicated for both PsO
and PsA, and as such, select subclinical PsA symptoms may
already have been treated, thus affecting the patients’ responses
to the PEST and potentially reducing their scores. Furthermore,
no corrections for potential confounders in the multivariate
analyses were performed. Further research is needed to charac-
terize patients by individual PEST score and to assess outcomes
over time.
In conclusion, using the validated PEST, over one-tenth of
patients with PsO enrolled in the US-based Corrona PsO Regis-
try were identified as having PEST scores of ≥3, raising the possi-
bility that many of these patients could have undiagnosed PsA
and highlighting a need for improved screening for PsA in der-
matology settings. Appropriate and earlier care of these patients
with possible undiagnosed PsA is important because they are
more likely to have nail PsO, higher activity impairment and
worse health-related quality of life.
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